<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01207752</url>
  </required_header>
  <id_info>
    <org_study_id>SCCO 10-6</org_study_id>
    <nct_id>NCT01207752</nct_id>
  </id_info>
  <brief_title>The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction</brief_title>
  <official_title>Evaluation of the Efficacy of an Ocular Emulsion on the Signs and Symptoms of Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California College of Optometry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California College of Optometry</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study will be to determine the efficacy of this novel, lipid-containing
      artificial tear on the signs and symptoms of meibomian gland disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear film breakup time</measure>
    <time_frame>Measured 2 hours after in-office administration of a single drop of test solution</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Systane Balance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artificial tear emulsion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optive Lubricant Eye Drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artificial tear</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systane Balance</intervention_name>
    <description>Artificial tear emulsion drop</description>
    <arm_group_label>Systane Balance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optive Lubricant Eye Drops</intervention_name>
    <description>Artificial tear eye drop</description>
    <arm_group_label>Optive Lubricant Eye Drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schein symptom score (all 6 questions) of greater than 5,

          -  evidence of MGD changes in both eyes (i.e.,

          -  lower eyelid secretion quality score greater than 1.0 (0 - 3 scale) OR gland dropout
             score greater than 1.0 (i.e., greater than 25% of entire lower eyelid) as demonstrated
             by meiboscopy, and corneal staining of grade 4.0 or greater (0 - 20 scale).

        Exclusion Criteria:

          -  contact lens wear, use of topical ocular medication other than artificial tears (use
             of Restasis is specifically excluded),

          -  unstable systemic medication use (i.e., anti-histamines, steroids, etc.), recent
             (within 6 months of study start) ocular trauma or surgery,

          -  diabetes, aqueous deficient dry eye (defined as a Schirmer I value (without
             anesthetic) of &lt; 5 mm of wetting in 5 minutes in either eye), and use of punctal
             plugs.

        -Subjects taking omega 3 fatty acid supplements for dry eye can be included so long as
        their intake is stable for the prior six months and they meet the inclusion criteria above.
        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry R Paugh, OD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern California College of Optometry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Care Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2010</study_first_submitted>
  <study_first_submitted_qc>September 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <last_update_submitted>May 31, 2013</last_update_submitted>
  <last_update_submitted_qc>May 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern California College of Optometry</investigator_affiliation>
    <investigator_full_name>Jerry R. Paugh, OD, PhD</investigator_full_name>
    <investigator_title>Professor, Associate Dean for Research</investigator_title>
  </responsible_party>
  <keyword>dry eye, meibomian gland dysfunction, tear film break up time</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 26, 2016</submitted>
    <returned>February 23, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

